Revolution Medicines, Inc.

RVMD

US76155X1000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:57:57 2026-01-20 am EST			5-day change	1st Jan Change
118.14 ^USD	-1.78%		-0.55%	+49.77%

Jan. 13	Mizuho Adjusts Price Target on Revolution Medicines to $143 From $90, Maintains Outperform Rating	MT
Jan. 12	Revolution Medicines, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM

Health Care Down Amid Deal Skepticism -- Health Care Roundup

Published on 01/08/2026 at 06:39 pm EST

Dow Jones

REVOLUTION MEDICINES, INC.

-1.78%

ABBVIE INC.

-1.21%

NEOGEN CORPORATION

-0.16%

Health-care companies fell amid skepticism about deal activity.

AbbVie denied it was in talks to buy cancer-drug biotech Revolution Medicines, weighing on both stocks.

Shares of Neogen rose after the food safety company reported stronger-than-expected quarterly results and boosted its fiscal-year guidance.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-08-26 1838ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
REVOLUTION MEDICINES, INC.	118.14USD	-1.78%	-0.55%	23.25B
ABBVIE INC.	211.76USD	-1.21%	-4.09%	379B
NEOGEN CORPORATION	9.235USD	-0.16%	-0.11%	2.01B

Latest news about Revolution Medicines, Inc.

Jan. 13	Mizuho Adjusts Price Target on Revolution Medicines to $143 From $90, Maintains Outperform Rating	MT
Jan. 12	Revolution Medicines, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM
Jan. 09	Health Care Up Amid Deal Speculation -- Health Care Roundup	DJ
Jan. 09	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Jan. 09	Sector Update: Health Care Stocks Mixed Friday Afternoon	MT
Jan. 09	Sector Update: Health Care	MT
Jan. 09	Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals	MT
Jan. 09	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026	RE
Jan. 09	Wall Street Gains Momentum Amid Jobs Report as US Equity Futures Edge Higher Pre-Bell	MT
Jan. 09	Wedbush Raises Price Target on Revolution Medicines to $147 From $80, Keeps Outperform Rating	MT
Jan. 09	Top Premarket Gainers	MT
Jan. 09	Merck reportedly consiering a major acquisition (Revolution Medicines)
Jan. 09	Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal	CI
Jan. 08	Health Care Down Amid Deal Skepticism -- Health Care Roundup	DJ
Jan. 08	Merck & Co. in Talks to Acquire Revolution Medicines	MT
Jan. 08	Price tag of $28bn to $32bn was being discussed as part of Merck-Revolution Medicines deal - FT	RE
Jan. 08	Merck in talks to buy biotech Revolution in up to $32 billion deal, FT reports	RE
Jan. 08	Merck in talks to buy biotech Revolution Medicines, Financial Times reports	RE
Jan. 08	Merck in talks to buy cancer drugmaker Revolution Medicines-FT	RE
Jan. 08	Revolution Medicines Says Zoldonrasib Gets US FDA Breakthrough Therapy Designation in Lung Cancer	MT
Jan. 08	Revolution Medicines, Inc. Announces FDA Breakthrough Therapy Designation for Zoldonrasib	CI
Jan. 08	Peace Was Cheaper
Jan. 08	Revolution Medicines announces FDA Breakthrough Therapy Designation for Zoldonrasib	RE
Jan. 08	Wall St mixed as tech retreats; defense firms gain on Trump's budget hike call	RE
Jan. 08	PRESS DIGEST-Wall Street Journal - January 8	RE

Chart Revolution Medicines, Inc.

Duration

Period

RVMD: Dynamic Chart

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Employees

809

Sector

Biotechnology & Medical Research

Calendar

Mar. 01 - Q4 2025 Earnings Release (Projected)

More about the company